Trials / Terminated
TerminatedNCT03921073
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
A Phase II Study of Talimogene Laherparepvec (T-VEC) in the Treatment of Locally Advanced Cutaneous Angiosarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T-VEC | Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion. |
Timeline
- Start date
- 2019-08-20
- Primary completion
- 2021-09-28
- Completion
- 2021-09-28
- First posted
- 2019-04-19
- Last updated
- 2022-11-01
- Results posted
- 2022-11-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03921073. Inclusion in this directory is not an endorsement.